It promotes breast cancer tumorigenesis by activating ERα-target genes or repressing BRMS1 expression and protects breast cancer cells from immune surveillance by repressing type I interferons and interferon-stimulated genes [36,142]. The gene discussed is BRMS1; the disease is breast carcinoma.